- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04407585
Testing the Accuracy of a Digital Test to Diagnose Covid-19
Validation of Machine Learning (ML) Models as Diagnostic Tools to Predict Infection With SARS-CoV-2
The Covid-19 viral pandemic has caused significant global losses and disruption to all aspects of society. One of the major difficulties in controlling the spread of this coronavirus has been the delayed and mild (or lack of) presentation of symptoms in infected individuals, and the insufficient Covid-19 testing capacity in the UK. This warrants the development of alternative diagnostic tools that reliably assess Covid-19 infection in the early stages of infection, while also being low- cost, low-burden, and easily administered to a wide proportion of the population.
This study aims to validate machine learning models as a diagnostic tool that predicts infection with SARS-CoV-2 based on app-reported symptoms and phenotypic data, against the 'gold-standard' swab PCR-test. This study will take place within the Covid Symptom Study app, the free symptom tracking mobile application launched in March 2020.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Covid-19 viral pandemic has caused significant global losses and disruption to all aspects of society (including health, education, and business and economic security). One of the major difficulties in controlling the spread of this coronavirus has been the delayed and mild (or lack of) presentation of symptoms in infected individuals. Moreover, there is insufficient Covid-19 testing capacity in the UK, and only moderate accuracy of such tests at confirming coronavirus infection. Together, these obstacles have led to countless unknown coronavirus cases going unobserved and fuelling the viral spread in the population, by compromising the stringency of self- isolation measures undertaken by infected individuals who may have otherwise curbed or prevented their transmission of the virus. The profound and widespread cost of the continuing Covid-19 progression, coinciding with the lack of testing capacity, warrants the development of alternative diagnostic tools that reliably assess Covid-19 infection in the early stages of infection, while also being low- cost, low-burden, and easily administered to a wide proportion of the population.
The free symptom-monitoring app 'Covid Symptom Study' was launched in mid-March by health technology start-up Zoe Global Ltd, and is currently being used in the UK, US and Sweden, with more than 2.7 million users in the UK alone who use the app to self-report their Covid-19 symptoms. Upon registering to use the app, users are asked to report demographic and phenotypic data such as age, sex, BMI, ethnicity, contact with infected individuals (through a healthcare professional capacity), smoking behaviour, existing health conditions, among other information. From then on, users are asked to report, on a daily basis, their presentation of symptoms attributable to Covid-19 (or lack thereof) through the use of app-administered questionnaires, thus enabling real-time tracking of disease progression across the UK. The app also allows users to report their Covid-19 test results, thus enabling the development of prediction algorithms based solely on self-reported user data to predict the presence of infection in untested users.
On behalf of Zoe Global Ltd, the UK Department of Health and Social Care with support from the UK's Chief Scientific Advisor has committed to test up to 10,000 app-users per week for infection with SARS-CoV-2 across England and Northern Ireland, for the purpose of rapidly improving the accuracy of symptom-based predictions. Similar testing allowance may follow in Scotland and Wales.
Symptomatic app-users will be asked to get tested for SARS-CoV-2 infection, using the popular swab and qRT-PCR technique, and asked to report their test results in the app, while continuing to log their symptoms.
This validation study, conducted at King's College London, aims to validate the sensitivity and specificity of machine learning models as a diagnostic tool that predicts infection with SARS-CoV-2 based on app-reported symptoms and phenotypic data, against the 'gold-standard' swab PCR-test, by utilising the Covid Symptom Study app as a research platform.
It is hypothesised that by training the symptom-based models using swab test results and through multiple model iterations following continuous data input from reporting and tested app users, predictions of infection will be made with considerable accuracy, thus enabling the Covid Symptom Study app to be used as a diagnostic tool that alleviates the strain of testing capacity in the UK while being easily accessible and posing low user burden.
Study Design:
Due to the rapidly developing and uncertain duration and intensity of the Covid-19 pandemic, the present study design is prospective and one that enables regular iteration on prediction models and continuous accumulation of validation data. The study consists of a series of phases, each lasting 14 days. Before the start of each phase (day 0), a set of machine learning models will be frozen and submitted for validation on data collected during this and subsequent phases.
Machine learning algorithms improve with increasing data. Therefore, validation phases will continue as long as tests are available and app users consent to joining the study. Due to the uncertainty around the progression of UK infection rates, the validation study will be continue whilst it is of value to public health.
A detailed statistical analysis plan is described in the document attached to this record. A record of all machine learning models used for validation will be regularly updated on GitHub (https://github.com/zoe/covid-validation-study).
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Inbar Linenberg, MSc
- Phone Number: +447791871699
- Email: inbar.linenberg@kcl.ac.uk
Study Locations
-
-
-
London, United Kingdom, SE1 9NH
- Recruiting
- King's College London
-
Contact:
- Inbar Linenberg, MSc
- Phone Number: +447791871699
- Email: inbar.linenberg@kcl.ac.uk
-
Principal Investigator:
- Tim Spector
-
Sub-Investigator:
- Sarah Berry
-
Sub-Investigator:
- Claire Steves
-
Sub-Investigator:
- Sebastien Ourselin
-
Sub-Investigator:
- Peter Sasieni
-
Sub-Investigator:
- Andrew Chan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Study Inclusion Criteria - app users will be eligible to join the study if they:
- Are based in the UK (are using the UK version of the Covid-19 Symptom Study app, and have listed a UK postcode)
- Are the primary app user (are reporting directly for themselves)
- Are at least 18 years of age
- Have not tested positive for a Covid-19 test before (but may have been tested)
Study Exclusion Criteria - participants are ineligible for the study if they:
- Do not meet inclusion criteria
- Do not provide informed consent to participate
Participants will be subject to further screening to identify them as eligible for swab testing during the course of the study.
Swab inclusion criteria - participants will be eligible for swab testing if they:
- Have reported in the app at least once in the previous 3 days (days -2 to 0), and at least two times in the previous 9 days (days -8 to 0). All reports must be healthy (i.e. not experiencing any symptoms).
- On the previous day (day 1), have reported that they are experiencing at least one symptom described in the app. Symptoms in the app are updated when deemed appropriate by study investigators using evidence based reports in the scientific and medical field.
- Have answered the phenotype fields required for the prediction model with physiologically plausible values.
Swab exclusion criteria - participants are ineligible for swab testing if they:
- Are asymptomatic
- Do not satisfy the inclusion criteria for testing.
Insufficient testing capacity:
If insufficient testing capacity is available for the study population as described, then recruitment will be prioritised according to:
- Firstly, most recent final healthy report before reporting symptoms
- Secondly, highest number of healthy reports during the previous 9 days before reporting symptoms
- Thirdly, randomised selection to stratify between participants of equal priority according to the first two rules above.
Excess testing capacity:
If excess testing capacity is available beyond the study population as described, then inclusion criteria will be expanded in order to adequately sample across under-represented population groups.
Specifically, on day 7 of each validation phase, investigators will assess:
- What excess testing capacity is available, if any
Which subgroups are under-represented compared to their proportion in the UK population (as best as can be established given that some participants may not have completed some phenotype fields):
(i) Age decade (ii) Sex (iii) Ethnicity (iv) BMI category
For underrepresented groups, investigators may additionally recruit participants with only one report during the previous 3 days (days -2 to 0) and no other report during the previous 9 days (days -8 to 0).
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Covid-19 Symptom Study app-user
UK-based Covid-19 Symptom Study primary app-user completing self-reports in the app
|
Participants satisfying machine learning test criteria will be asked to take a swab test for Covid-19.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SARS-CoV-2 infection
Time Frame: 3 days
|
Likelihood of infection with Covid-19, based on app-reported symptoms
|
3 days
|
SARS-CoV-2 infection
Time Frame: 1 day
|
Active infection with Covid-19 as assessed by PCR swab test
|
1 day
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Covid-19 Validation Study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on Covid-19 swab PCR test
-
Aarhus University HospitalWithdrawnStroke, Acute | Seizure Disorder | Neurological Diseases or ConditionsDenmark
-
Cairo UniversityCompleted
-
Acibadem UniversityCompleted
-
Assiut UniversityCompletedAssess the Outcome for Children With Covid-19 Admitted in Assuit University Children HospitalEgypt
-
University Hospital, ToulouseCompleted
-
BioTeke USA, LLCCSSi Life SciencesCompleted
-
Mach-E B.V.Completed
-
King's College LondonGuy's and St Thomas' NHS Foundation TrustUnknownCovid19United Kingdom
-
University of RochesterEunice Kennedy Shriver National Institute of Child Health and Human Development...Active, not recruiting
-
EDP BiotechParagon Rx Clinical, Inc.; iCura Diagnostics, LLCCompleted